S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Laser breakthrough could send stock soaring 2,467% (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Laser breakthrough could send stock soaring 2,467% (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Laser breakthrough could send stock soaring 2,467% (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Laser breakthrough could send stock soaring 2,467% (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Forecast, Price & News

$0.60
-0.01 (-1.65%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.58
$0.62
50-Day Range
$0.51
$1.05
52-Week Range
$0.51
$4.37
Volume
1.51 million shs
Average Volume
1.47 million shs
Market Capitalization
$113.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
Reduce
1.80 Rating Score
Upside/​Downside
403.7% Upside
$3.00 Price Target
Short Interest
Healthy
3.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.44mentions of Nektar Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$26,174 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.00) to ($0.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

398th out of 972 stocks

Pharmaceutical Preparations Industry

170th out of 445 stocks


NKTR stock logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR Price History

NKTR Stock News Headlines

WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
Nektar Therapeutics Q2 Loss decreases, beats estimates
Howard Robin seeks another turnaround at Nektar
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings
8/08/2023
Today
9/30/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
216
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+403.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

Net Income
$-368,200,000.00
Net Margins
-349.75%
Pretax Margin
-346.47%

Debt

Sales & Book Value

Annual Sales
$92.06 million
Book Value
$1.95 per share

Miscellaneous

Free Float
184,282,000
Market Cap
$113.24 million
Optionable
Optionable
Beta
1.00

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Howard W. RobinMr. Howard W. Robin (Age 70)
    CEO, Pres & Director
    Comp: $1.83M
  • Mr. Mark A. Wilson (Age 51)
    Sr. VP, Chief Legal Officer & Sec.
    Comp: $749.99k
  • Dr. Jonathan Zalevsky Ph.D. (Age 48)
    Sr. VP & Chief R&D Officer
    Comp: $1.25M
  • Ms. Sandra A. Gardiner (Age 57)
    Chief Financial Officer
  • Vivian Wu
    Director of Investor Relations & Corp. Affairs
  • Mr. Robert Bacci
    Sr. VP of HR & Facilities Operations
  • Ms. Jennifer Ruddock
    Chief Bus. Officer
  • Dr. Mary Tagliaferri L.Ac. (Age 57)
    M.D., Chief Medical Officer
  • Dr. Loui T. Madakamutil
    VP and Head of Discovery & Research













NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NKTR shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2023?

5 Wall Street research analysts have issued 12 month target prices for Nektar Therapeutics' shares. Their NKTR share price forecasts range from $1.00 to $6.00. On average, they anticipate the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 403.7% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2023?

Nektar Therapeutics' stock was trading at $2.26 at the beginning of 2023. Since then, NKTR shares have decreased by 73.6% and is now trading at $0.5956.
View the best growth stocks for 2023 here
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) issued its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The biopharmaceutical company had revenue of $20.50 million for the quarter, compared to the consensus estimate of $20.94 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 67.03% and a negative net margin of 349.75%. During the same period last year, the business earned ($0.85) EPS.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $0.60.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $113.24 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

The company employs 216 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -